Please Wait
Applying Filters...
menu
    • menu
    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Actinium-225

    ACTIVE PHARMA INGREDIENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cellectar Bio Inks Actinium-225 Deal With Ionetix
    Cellectar Bio Inks Actinium-225 Deal With Ionetix

    16 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/16/3206203/29076/en/Cellectar-Biosciences-Announces-Strategic-Supply-Agreement-with-Ionetix-for-Actinium-225-and-Astatine-211-to-Advance-Targeted-Alpha-Therapies.html

    GLOBENEWSWIRE
    16 Dec 2025
    Share Share
    Alpha-9 Oncology Initiates Phase 1 Trial For A9-3408 In Melanoma
    Alpha-9 Oncology Initiates Phase 1 Trial For A9-3408 In Melanoma

    04 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alpha-9-oncology-announces-first-patient-dosed-in-phase-1-study-of-a9-3408-for-the-treatment-of-melanoma-302632371.html

    PR NEWSWIRE
    04 Dec 2025
    Share Share
    Actinium Reveals ATNM-400's Strong Efficacy in Breast Cancer
    Actinium Reveals ATNM-400's Strong Efficacy in Breast Cancer

    01 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-atnm-400-data-demonstrating-potent-efficacy-in-triple-negative-breast-cancer-and-ability-to-overcome-endocrine-and-her2-targeted-therapy-resistance-being-presented-at-the-san-antonio-breast-cance-302629128.html

    PR NEWSWIRE
    01 Dec 2025
    Share Share
    AtomVie Delivers First 225Ac-SSO110 Dose for Ariceum Ph1/2 Trial
    AtomVie Delivers First 225Ac-SSO110 Dose for Ariceum Ph1/2 Trial

    12 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/atomvie-global-radiopharma-supplies-the-first-patient-dose-of-225ac-sso110-for-ariceum-therapeutics-phase-12-santana-225-clinical-trial-in-extensive-stage-small-cell-lung-cancer-and-merkel-cell-carcinoma-302612102.html

    PR NEWSWIRE
    12 Nov 2025
    Share Share
    Ariceum Doses First Patient In SANTANA-225 Ph1/2 Trial
    Ariceum Doses First Patient In SANTANA-225 Ph1/2 Trial

    11 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/11/3185185/0/en/Ariceum-Therapeutics-Doses-First-Patient-in-SANTANA-225-Phase-1-2-Clinical-Trial-of-225Ac-SSO110-in-Patients-with-Extensive-Stage-Small-Cell-Lung-Cancer-or-Merkel-Cell-Carcinoma.html

    GLOBENEWSWIRE
    11 Nov 2025
    Share Share
    Nusano, Ariceum Therapeutics Ink Multi-Isotope Supply Deal
    Nusano, Ariceum Therapeutics Ink Multi-Isotope Supply Deal

    14 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/14/3166030/0/en/Nusano-and-Ariceum-Therapeutics-Announce-Multi-Isotope-Supply-Agreement.html

    GLOBENEWSWIRE
    14 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.